Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.